Revenue
2011
2012
2013
2014
2015
2022
2023
2024
2025
Atossa Therapeutics, Inc. (ATOS)
Price$2.52Cached quote
Net income
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2011
2012
2013
2014
2015
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | — | — | — | — | — | — | $1,758 | $40,138 | $632,558 | $481,842 | $1,500 | — |
| Gross profit | — | — | — | — | — | — | — | — | — | — | −$130,653 | $40,138 | $137,093 | $416,213 | −$95,690 | — |
| Gross margin | — | — | — | — | — | — | — | — | — | — | −7,431.91% | 100.00% | 21.67% | 86.38% | −6,379.33% | — |
| Research & development | $21.2M | $14.1M | $17.3M | $15.1M | $9.2M | $6.6M | $6.6M | $4.2M | $2.3M | $770,427 | $2.4M | $1.1M | $1.1M | $2.0M | — | — |
| Operating expenses | $37.1M | $27.6M | $31.4M | $27.7M | $20.5M | $14.6M | $17.3M | $11.4M | $7.6M | $8.0M | $12.6M | $12.2M | $10.9M | $5.5M | $3.3M | — |
| Operating income | −$37.1M | −$27.6M | −$31.4M | −$27.7M | −$20.5M | −$14.6M | −$17.3M | −$11.4M | −$7.6M | −$8.0M | −$12.8M | −$12.2M | −$10.8M | −$5.1M | −$3.4M | — |
| Operating margin | — | — | — | — | — | — | — | — | — | — | −725,746.19% | −30,322.96% | −1,704.93% | −1,052.01% | −228,612.67% | — |
| EBITDA | −$37.1M | −$27.6M | −$31.4M | −$27.7M | −$20.5M | −$14.6M | −$17.2M | −$11.4M | −$7.5M | −$7.7M | −$12.5M | −$11.7M | −$10.3M | −$4.9M | −$3.4M | — |
| EBITDA margin | — | — | — | — | — | — | — | — | — | — | −710,238.40% | −29,126.30% | −1,630.16% | −1,024.92% | −227,571.13% | — |
| Net income | −$34.8M | −$25.5M | −$30.1M | −$27.0M | −$20.6M | −$17.8M | −$17.2M | −$11.4M | −$8.1M | −$6.4M | −$15.8M | −$14.7M | −$10.8M | −$5.1M | −$3.4M | −$1.1M |
| Net profit margin | — | — | — | — | — | — | — | — | — | — | −896,491.64% | −36,518.83% | −1,704.94% | −1,054.26% | −229,484.53% | — |
| Basic EPSper basic share | -$4.04 | -$3.04 | -$53.73 | -$47.01 | -$40.30 | -$441.04 | -$454.48 | -$1,231.34 | -$2,455.97 | -$5,802.99 | -$22,325.37 | -$1,638.81 | -$1,880.60 | -$1,101.49 | -$1,020.90 | — |
| Diluted EPSper diluted share | -$4.04 | -$3.04 | -$53.73 | -$47.01 | -$40.30 | -$441.04 | -$454.48 | -$1,231.34 | -$2,455.97 | -$5,802.99 | -$22,325.37 | -$1,638.81 | -$1,880.60 | -$1,101.49 | -$1,020.90 | — |
Owners
Reported shareholders
3.62%of listed shares
VANGUARD CAPITAL MANAGEMENT LLC361.75K shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
VANGUARD CAPITAL MANAGEMENT LLC | 3.62%361.75K shares |
AMERIPRISE FINANCIAL INC | 2.59%258.23K shares |
BlackRock, Inc. | 1.65%164.36K shares |
RENAISSANCE TECHNOLOGIES LLC | 1.32%132.04K shares |
GEODE CAPITAL MANAGEMENT, LLC | 0.93%92.38K shares |
QUAY STEVEN C | —89.52K shares |
UBS Group AG | 0.83%82.62K shares |
Daniel Mark James | ≈0.63%63K shares |
JANE STREET GROUP, LLC | 0.57%56.6K shares |
VANGUARD FIDUCIARY TRUST CO | 0.53%52.58K shares |
MILLENNIUM MANAGEMENT LLC | 0.47%46.51K shares |
STATE STREET CORP | 0.40%39.76K shares |
NORTHERN TRUST CORP | 0.20%20.25K shares |
SUSQUEHANNA INTERNATIONAL GROUP, LLP | 0.16%15.57K shares |
MORGAN STANLEY | 0.12%12.35K shares |
Finn Jonathan | ≈0.12%11.67K shares |
Chen Shu-Chih | ≈0.12%11.48K shares |
Remmel H. Lawrence | ≈0.11%10.68K shares |
Galli Stephen J | ≈0.10%10.01K shares |
Steinhart Richard I | ≈0.10%10K shares |
Percentages use 9.98M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| May 21, 2025Form 4 | QUAY STEVEN CPresident & CEO | BuyCommon Stock | 11.2K | $0.88 | $9.9K | 13.9K |
| Mar 26, 2025Form 4 | Remmel H. LawrenceDirector | BuyCommon Stock | 10.0K | $0.70 | $7.0K | 10.3K |